The deal is on track with regulatory clearance obtained. The key remaining catalyst is the shareholder vote. Monitor for any competing bids or significant shareholder dissent that could delay or alter terms. The CVR provides optionality on ampreloxetine, but its value is highly speculative and dependent on Zymeworks' actions.
Drug in focus
TBPH drug pipeline →ampreloxetine
▼ Bearish Named in this PREM14A- Impact
- Phase
- Phase 3 (failed)
- Time to market
- Not applicable. The drug failed all Phase 3 trials and development has been terminated.
- Next catalyst
- None dated
What to watchAmpreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 11 $16.91entry
- T+1 · 3mo ago +0.06%α −0.19% · $16.92
- T+5 · 3mo ago +0.24%α +0.64% · $16.95
- T+20 · 2mo ago +0.89%α +1.95% · $17.06
- T+60 · due 13d ago Pending
Price Chart
Executive Summary
Theravance Biopharma (TBPH) filed a preliminary proxy statement (PREM14A) for an extraordinary general meeting to approve its acquisition by Zymeworks Inc. (ZYME) for $17.00 per share in cash plus one non-tradable contingent value right (CVR) per share tied to future monetization of ampreloxetine. The all-cash deal values TBPH at approximately $928M equity value, with the board unanimously recommending approval. The HSR waiting period has been terminated early, and the deal is expected to close in H2 2026, subject to shareholder vote and other customary conditions.
Key Financial Metrics
Key Facts
- TBPH shareholders to receive $17.00 per share in cash plus one CVR per share.
- CVR provides 80% of net proceeds from any ampreloxetine monetization within 10 years, a $50M milestone on first commercial sale, and 10% royalties on net sales.
- Theravance Biopharma board unanimously recommends voting FOR the merger.
- HSR Act waiting period terminated early on August 4, 2026.
- Zymeworks has secured a $350M debt commitment from OMERS Life Sciences; no financing condition.
- Lazard rendered a fairness opinion that the $17.00 per share plus CVR is fair from a financial point of view.
- Termination fee of $32,515,000 payable by either party under specified circumstances.
- Shareholder vote requires approval of at least two-thirds of shares present and voting.
- Dissenters' rights available under Cayman Islands law.
- Proposed maximum aggregate transaction value is $928,265,233.23.
Financial Impact
All-cash consideration of $17.00 per share values TBPH at approximately $928M equity value. CVR provides contingent upside tied to ampreloxetine monetization, with a $50M milestone and 10% royalties.
Risk Factors
- Shareholder vote may not be obtained.
- CVR payments are highly speculative and may never materialize.
- Potential litigation challenging the merger.
- Execution risk related to Zymeworks' financing and integration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (TBPH), Batch item 1 | 0001104659-26-093784 |
| Document: tm2621435d1_ex-filingfees.htm | 0001104659-26-093784 |
| Document: 0001104659-26-093784-index-headers.html | 0001104659-26-093784 |
| Document: 0001104659-26-093784-index.html | 0001104659-26-093784 |
| Document: 0001104659-26-093784.txt | 0001104659-26-093784 |
Track record
12 reports on TBPH
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
- Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
- Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
- Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
- Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
- Aug 11, 202613w ago PREM14A Bullish 7/10 Viewing Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers